Recent Updates
Recently added Catalysts
HEAL Positive Sentiment

Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth

Key Takeaway: Restart Life Sciences Corp. reported a significant 146% sequential revenue growth in Q2 2026, transitioning from a non-revenue issuer to a revenue-producing consumer packaged goods business. The company generated $465,715 in revenue for the first half of 2026, attributed to the acquisition of Holy Crap Foods Inc. and strategic market expansion efforts. CEO Steve Loutskou emphasized the focus on growth despite recognizing ongoing operational risks.

Market Sentiment Analysis

POSITIVE FACTORS

  • 146% sequential revenue growth indicates strong business momentum.
  • Successful transition from a non-revenue issuer to a revenue-generating entity.
  • Expansion into the U.S. market via Amazon shows strategic growth.
  • Maintained product margins across sales channels.

CONCERNS & RISKS

  • Ongoing costs and capital requirements pose risks to scaling.
  • Operational risks associated with integrating new acquisitions.

Full Press Release Details

We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use .
September 03, 2026 6:00 AM EDT | Source: Restart Life Sciences Corp.
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. All financial figures are expressed in Canadian dollars ($) unless otherwise noted, are prepared in accordance with International Financial Reporting Standards (IFRS), and are unaudited.
In the second quarter of 2026, Restart Life Sciences continued its operational transition following the acquisition of 100% of Holy Crap Foods Inc. ("Holy Crap") on February 26, 2026, shifting from a non-revenue issuer to a revenue-producing consumer packaged goods (CPG) business. The Company recorded quarter-over-quarter revenue growth and maintained its product margins across its sales channels.
"Our management team remains focused on strategic growth, revenue generation, and market expansion," stated Steve Loutskou, CEO of Restart Life. "Transitioning from a non-revenue issuer a year ago to reporting $465,715 in revenue for the first half of 2026 reflects the initial integration of our operations. With our presence on digital platforms, our entry into the U.S. market via Amazon, and our evaluation of potential M&A opportunities, we continue to execute our business plan, though we recognize the ongoing costs, capital requirements, and operational risks necessary to scale the business over the long term."
During the period and subsequent to the quarter end, the Company advanced several operational initiatives:
Restart Life Sciences would like to thank its shareholders for their ongoing support as the Company advances its mission and continues to
About Restart Life Sciences Corp. Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co .
About Holy Crap Foods Inc. Holy Crap Superseed Cereal and Holy Crap Superseed Oatmeal are premium functional food brands offering nutrient-dense, clean-label products made with simple, high-quality ingredients. Based in Gibsons, British Columbia, the brand has built a loyal and growing customer base across Canada, driven by strong consumer trust and repeat purchases.
Positioned within the fast-growing gut health and wellness category, Holy Crap's gluten-free, non-GMO, high-fiber products support digestive health and sustained energy, while gaining traction as a trusted, everyday solution for health-conscious consumers. For more information, visit www.holycrap.com
Forward-Looking Statements This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Sciences' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
On behalf of the Board of Directors Steve Loutskou Chief Executive Officer, Restart Life Sciences Corp. Tel: +1 (778) 819-0244 Email: hello@restartlife.co
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312691
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Frequently Asked Questions

What was Restart Life Sciences' revenue growth in Q2 2026?

Restart Life Sciences reported a 146% sequential revenue growth in Q2 2026.

What acquisition did Restart Life Sciences complete?

The company acquired 100% of Holy Crap Foods Inc. on February 26, 2026.

How much revenue did Restart Life Sciences generate in H1 2026?

The company generated $465,715 in revenue for the first half of 2026.

What market did Restart Life Sciences enter recently?

Restart Life Sciences entered the U.S. market via Amazon.

What risks does Restart Life Sciences face?

The company faces ongoing costs, capital requirements, and operational risks.

Last updated: Sep 3, 2026